It’s time to regulate PBM’s

  • PBMs often portray themselves as fighting the “good fight” on behalf of employers and employees.
  • In reality, they are highly profitable intermediaries that typically do not take possession of the drug, bear little to no risk, and minimally innovate.
  • PBM profit margins are much higher than other players in the supply chain who bear much of the public’s anger over rising drug prices.
  • Express Scripts for example, one of the largest PBMs, reported gross profits of $8.76 billion in 2017.

Continue reading

Cybercitizen Health® Insights

Data from DRG Digital | Manhattan Research’s Cybercitizen Health® U.S. 2018 study of 3,084 U.S. patients show that:

  • Among the 61% of patients who had researched prescription drugs online in the past 12 months, 34% had requested a specific prescription drug at least once.
  • Among patients who had requested an Rx, 25% were prompted to do so by a TV ad and 25% by ads seen online.
  • Among the 65% of patients who recalled seeing or hearing TV ads about prescription drugs in the past 12 months, 22% had requested a specific drug.
  • Among the 49% of patients who recalled seeing or hearing online ads, 42% had requested a specific Rx drug.
  • TV or online ads may be particularly effective at reaching some condition groups. Among online Rx researchers requesting a prescription, patients with multiple sclerosis, hypertension and Alzheimer’s Disease were particularly likely to cite TV ads as the impetus for their request, while patients with hepatitis C, type 1 diabetes and severe asthma were more likely to cite online ads.

Continue reading

Gilead exec’s flee after milking the health care system

  • Executives at Gilead are leaving a sinking ship.
  • Sales of a breakthrough drug they purchased through the acquisition of Kite Pharma  have failed to match expectations.
  • Gilead charges thousands of dollars for a drug for their AIDS drug, but competition is creeping in.
  • Since Truvada was approved for HIV prevention six years ago, its average wholesale price has increased by about 45 percent.
  • Without more drugs to buy Gilead’s stock has been declining.

Continue reading

Prescription drug pricing is out of control

  • The cost of insulin more than tripled — from $231 to $736 a year per patient — between 2002 and 2013.
  • A new marijuana-based epilepsy treatment is going to cost $32,500 a year.
  • “The goal is to keep the price of the drug on par with other epilepsy medications”.
  • PBM’s are driving hard bargains with the manufacturer and they are increasingly finding ways to expand their profitability at the expense of employers and patients.

Continue reading